2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
7
Gastrointestinal
5
Genitourinary
2
Thoracic
1
Head & Neck
1
Conditions
Urologic Neoplasms
1
Prostatic Neoplasms
1
Nephrolithiasis
1
Multicystic renal dysplasia, bilateral
1
Margins of Excision
1
Hematuria
1
Adenocarcinoma
1
Interventions
Docetaxel
409
pembrolizumab
332
Prednisone
290
enzalutamide
285
Gemcitabine
274
Radiotherapy
270
Magnetic Resonance Spectroscopy
269
Nivolumab
253
Abiraterone Acetate
218
Cisplatin
212
Leuprolide
195
Radiosurgery
192
Sunitinib
188
Carboplatin
161
Androgen Antagonists
156
bicalutamide
152
Specimen Handling
149
Goserelin
149
Ipilimumab
131
Paclitaxel
126
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
122
apalutamide
118
Cyclophosphamide
117
Bevacizumab
116
Sorafenib
114
Everolimus
111
abiraterone
108
cabozantinib
105
atezolizumab
105
Biopsy
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Microscopy, Confocal
×
Genitourinary
×
Clear all
NCT07541911
2026-05-18
LaserSAFE
University College, London
Phase NA
Recruiting
693 enrolled
NCT02276924
2025-12-24
UROVISIO
Lille Catholic University
Phase NA
Completed
29 enrolled